Neurogene Common Stock Shares Outstanding vs Other Current Liab Analysis

NGNE Stock

22.50 0.14 0.62%

Neurogene financial indicator trend analysis is infinitely more than just investigating Neurogene recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Neurogene is a good investment. Please check the relationship between Neurogene Common Stock Shares Outstanding and its Other Current Liab accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.

Common Stock Shares Outstanding vs Other Current Liab

Common Stock Shares Outstanding vs Other Current Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Neurogene Common Stock Shares Outstanding account and Other Current Liab. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Neurogene's Common Stock Shares Outstanding and Other Current Liab is -0.5. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Other Current Liab in the same time period over historical financial statements of Neurogene, assuming nothing else is changed. The correlation between historical values of Neurogene's Common Stock Shares Outstanding and Other Current Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Neurogene are associated (or correlated) with its Other Current Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Current Liab has no effect on the direction of Common Stock Shares Outstanding i.e., Neurogene's Common Stock Shares Outstanding and Other Current Liab go up and down completely randomly.

Correlation Coefficient

-0.5

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Other Current Liab

Most indicators from Neurogene's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Neurogene current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.As of December 24, 2024, Selling General Administrative is expected to decline to about 10.4 M. In addition to that, Issuance Of Capital Stock is expected to decline to about 76.8 M

	2022	2023	2024 (projected)
Net Interest Income	1.3M	2.9M	1.6M
Cost Of Revenue	3.2M	3.3M	2.4M

Net Interest Income Cost Of Revenue

Neurogene fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Accounts Payable	Short Term Debt	Current Deferred Revenue	Net Receivables	Capital Lease Obligations	Inventory
Total Assets		0.52	0.5	0.46	0.68	0.06	-0.39	-0.29	0.43	0.27	0.6	-0.31	0.86	-0.03	0.3	-0.4	0.16	0.62	-0.37	0.85	-0.04	0.44	0.53	-0.52	0.56	-0.03
Short Long Term Debt Total	0.52		0.54	0.77	0.17	0.67	-0.78	-0.31	0.74	-0.35	0.51	-0.8	0.69	0.13	-0.35	0.14	0.71	0.08	0.19	0.71	0.47	0.86	0.77	-0.58	0.75	-0.63
Other Current Liab	0.5	0.54		0.92	0.51	0.04	-0.04	0.23	-0.02	0.2	0.1	-0.78	0.39	-0.5	0.53	-0.33	0.12	0.08	-0.26	0.39	0.02	0.81	0.72	-0.73	0.73	-0.4
Total Current Liabilities	0.46	0.77	0.92		0.34	0.36	-0.3	0.15	0.23	0.0	0.1	-0.9	0.46	-0.25	0.21	-0.11	0.45	-0.04	-0.04	0.47	0.37	0.93	0.84	-0.8	0.84	-0.52
Total Stockholder Equity	0.68	0.17	0.51	0.34		-0.57	-0.17	-0.38	0.13	0.18	0.48	-0.32	0.6	-0.22	0.51	-0.93	-0.4	0.84	-0.91	0.58	-0.34	0.32	0.25	-0.68	0.32	0.31
Property Plant And Equipment Net	0.06	0.67	0.04	0.36	-0.57		-0.48	0.07	0.52	-0.3	0.05	-0.31	0.19	0.38	-0.6	0.79	0.95	-0.51	0.82	0.22	0.72	0.4	0.45	0.0	0.4	-0.61
Net Debt	-0.39	-0.78	-0.04	-0.3	-0.17	-0.48		0.79	-0.98	0.68	-0.74	0.48	-0.75	-0.35	0.69	-0.05	-0.51	-0.38	-0.07	-0.76	-0.32	-0.52	-0.45	0.34	-0.44	0.38
Retained Earnings	-0.29	-0.31	0.23	0.15	-0.38	0.07	0.79		-0.79	0.66	-0.85	0.07	-0.65	-0.29	0.52	0.32	0.04	-0.73	0.33	-0.64	0.16	-0.08	-0.04	0.13	-0.05	-0.05
Cash	0.43	0.74	-0.02	0.23	0.13	0.52	-0.98	-0.79		-0.67	0.76	-0.36	0.78	0.41	-0.7	0.08	0.54	0.4	0.1	0.79	0.33	0.45	0.46	-0.29	0.44	-0.31
Non Current Assets Total	0.27	-0.35	0.2	0.0	0.18	-0.3	0.68	0.66	-0.67		-0.42	0.2	-0.26	-0.28	0.76	-0.13	-0.3	-0.13	-0.13	-0.27	-0.23	-0.21	-0.19	0.09	-0.17	0.22
Non Currrent Assets Other	0.6	0.51	0.1	0.1	0.48	0.05	-0.74	-0.85	0.76	-0.42		-0.17	0.83	0.22	-0.26	-0.31	0.1	0.72	-0.3	0.83	-0.22	0.23	0.22	-0.21	0.23	-0.08
Other Assets	-0.31	-0.8	-0.78	-0.9	-0.32	-0.31	0.48	0.07	-0.36	0.2	-0.17		-0.41	0.28	0.03	0.09	-0.34	0.02	0.03	-0.42	-0.29	-0.95	-0.73	0.72	-0.71	0.65
Cash And Short Term Investments	0.86	0.69	0.39	0.46	0.6	0.19	-0.75	-0.65	0.78	-0.26	0.83	-0.41		0.11	-0.1	-0.36	0.3	0.71	-0.32	1.0	0.06	0.55	0.62	-0.57	0.64	-0.14
Common Stock Shares Outstanding	-0.03	0.13	-0.5	-0.25	-0.22	0.38	-0.35	-0.29	0.41	-0.28	0.22	0.28	0.11		-0.54	0.23	0.54	0.04	0.22	0.12	0.61	-0.29	-0.28	0.07	-0.25	0.39
Short Term Investments	0.3	-0.35	0.53	0.21	0.51	-0.6	0.69	0.52	-0.7	0.76	-0.26	0.03	-0.1	-0.54		-0.54	-0.52	0.15	-0.53	-0.11	-0.44	-0.03	0.01	-0.22	0.05	0.29
Non Current Liabilities Total	-0.4	0.14	-0.33	-0.11	-0.93	0.79	-0.05	0.32	0.08	-0.13	-0.31	0.09	-0.36	0.23	-0.54		0.61	-0.81	1.0	-0.33	0.44	-0.08	-0.04	0.56	-0.12	-0.53
Other Current Assets	0.16	0.71	0.12	0.45	-0.4	0.95	-0.51	0.04	0.54	-0.3	0.1	-0.34	0.3	0.54	-0.52	0.61		-0.36	0.65	0.32	0.85	0.44	0.49	-0.21	0.46	-0.41
Other Stockholder Equity	0.62	0.08	0.08	-0.04	0.84	-0.51	-0.38	-0.73	0.4	-0.13	0.72	0.02	0.71	0.04	0.15	-0.81	-0.36		-0.82	0.69	-0.39	0.05	0.1	-0.4	0.16	0.44
Total Liab	-0.37	0.19	-0.26	-0.04	-0.91	0.82	-0.07	0.33	0.1	-0.13	-0.3	0.03	-0.32	0.22	-0.53	1.0	0.65	-0.82		-0.3	0.47	-0.02	0.02	0.5	-0.06	-0.57
Total Current Assets	0.85	0.71	0.39	0.47	0.58	0.22	-0.76	-0.64	0.79	-0.27	0.83	-0.42	1.0	0.12	-0.11	-0.33	0.32	0.69	-0.3		0.08	0.56	0.63	-0.57	0.65	-0.15
Accounts Payable	-0.04	0.47	0.02	0.37	-0.34	0.72	-0.32	0.16	0.33	-0.23	-0.22	-0.29	0.06	0.61	-0.44	0.44	0.85	-0.39	0.47	0.08		0.32	0.31	-0.33	0.32	-0.11
Short Term Debt	0.44	0.86	0.81	0.93	0.32	0.4	-0.52	-0.08	0.45	-0.21	0.23	-0.95	0.55	-0.29	-0.03	-0.08	0.44	0.05	-0.02	0.56	0.32		0.9	-0.77	0.89	-0.65
Current Deferred Revenue	0.53	0.77	0.72	0.84	0.25	0.45	-0.45	-0.04	0.46	-0.19	0.22	-0.73	0.62	-0.28	0.01	-0.04	0.49	0.1	0.02	0.63	0.31	0.9		-0.71	0.99	-0.54
Net Receivables	-0.52	-0.58	-0.73	-0.8	-0.68	0.0	0.34	0.13	-0.29	0.09	-0.21	0.72	-0.57	0.07	-0.22	0.56	-0.21	-0.4	0.5	-0.57	-0.33	-0.77	-0.71		-0.77	0.01
Capital Lease Obligations	0.56	0.75	0.73	0.84	0.32	0.4	-0.44	-0.05	0.44	-0.17	0.23	-0.71	0.64	-0.25	0.05	-0.12	0.46	0.16	-0.06	0.65	0.32	0.89	0.99	-0.77		-0.45
Inventory	-0.03	-0.63	-0.4	-0.52	0.31	-0.61	0.38	-0.05	-0.31	0.22	-0.08	0.65	-0.14	0.39	0.29	-0.53	-0.41	0.44	-0.57	-0.15	-0.11	-0.65	-0.54	0.01	-0.45

Click cells to compare fundamentals

Neurogene Account Relationship Matchups

Neurogene fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	147.0M	210.5M	101.5M	109.3M	222.6M	155.8M
Short Long Term Debt Total	1.2M	12.1M	5.2M	4.7M	16.3M	17.1M
Other Current Liab	2.5M	5.9M	4.6M	5.3M	17.5M	18.4M
Total Current Liabilities	4.7M	7.9M	10.9M	6.7M	23.0M	24.1M
Total Stockholder Equity	141.7M	191.2M	(91.9M)	(145.7M)	186.0M	195.3M
Property Plant And Equipment Net	2.8M	13.7M	27.5M	24.5M	21.0M	12.6M
Net Debt	(141.9M)	(180.4M)	(65.3M)	(77.3M)	(132.0M)	(138.6M)
Retained Earnings	(299.5M)	(332.8M)	(95.6M)	(150.8M)	(187.2M)	(196.5M)
Cash	143.1M	192.6M	70.5M	82.0M	148.2M	109.7M
Non Current Assets Total	3.4M	16.0M	27.5M	24.5M	22.2M	20.2M
Non Currrent Assets Other	597.0K	2.3M	(878K)	87K	764K	480.6K
Cash And Short Term Investments	143.1M	192.6M	70.5M	82.0M	197.2M	133.8M
Common Stock Shares Outstanding	27.0M	51.8M	55.0M	12.8M	14.7M	14.0M
Liabilities And Stockholders Equity	147.0M	210.5M	101.5M	109.3M	222.6M	155.8M
Non Current Liabilities Total	593K	11.4M	182.5M	248.4M	13.6M	12.9M
Other Current Assets	503K	2.0M	3.4M	1.7M	2.6M	1.6M
Other Stockholder Equity	441.2M	524.0M	3.8M	5.1M	373.2M	224.1M
Total Liab	5.3M	19.3M	193.4M	255.0M	36.5M	34.7M
Total Current Assets	143.6M	194.5M	74.0M	84.7M	200.3M	135.7M
Accounts Payable	1.6M	1.3M	5.6M	625K	2.6M	2.3M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:

How To Invest In Neurogene

Details

Is Neurogene Stock a good investment?

Details

What is Neurogene's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.

You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.66)

Revenue Per Share

0.106

Return On Assets

(0.32)

Return On Equity

(0.41)

The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Neurogene Common Stock Shares Outstanding vs Other Current Liab Analysis

Common Stock Shares Outstanding vs Other Current Liab

Common Stock Shares Outstanding vs Other Current Liab Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Other Current Liab

Neurogene fundamental ratios Correlations

Neurogene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Neurogene fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Total Liab	+ 1.0	Non Current Liabilities Total
Capital Lease Obligations	+ 0.99	Current Deferred Revenue
Other Current Assets	+ 0.95	Property Plant And Equipment Net
Short Term Debt	+ 0.93	Total Current Liabilities
Total Current Liabilities	+ 0.92	Other Current Liab

Cash	- 0.98	Net Debt
Short Term Debt	- 0.95	Other Assets
Non Current Liabilities Total	- 0.93	Total Stockholder Equity
Total Liab	- 0.91	Total Stockholder Equity
Other Assets	- 0.9	Total Current Liabilities
Non Currrent Assets Other	- 0.85	Retained Earnings